Aurinia Pharmaceuticals (US:AUPH) — Company Overview, News & Financial Data

Aurinia Pharmaceuticals logo
AUPHAurinia Pharmaceuticals
Trade AUPH now
Aurinia Pharmaceuticals primary media

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals (NASDAQ:AUPH) specializes in the development and commercialization of therapies aimed at treating targeted patient populations suffering from serious diseases with a high unmet medical need. Its primary focus is on autoimmune diseases, particularly in the realm of nephrology and autoimmunity. A key project for Aurinia is its innovative drug, voclosporin, designed specifically for the treatment of lupus nephritis, a severe and potentially life-threatening condition. The objective of Aurinia is to achieve breakthroughs in patient care by advancing these treatments through rigorous clinical trials and regulatory pathways, aiming to bring new hope and therapeutic options to patients and healthcare providers worldwide.

What is AUPH known for?

Snapshot

Public US
Ownership
2012
Year founded
297
Employees
Victoria, Canada
Head office
Loading Map...

Operations

All Locations
Canada

Products and/or services of Aurinia Pharmaceuticals

  • Lupkynis (voclosporin), an FDA-approved treatment for adults with active lupus nephritis.
  • Voclosporin oral solution, under investigation for use in pediatric patients with lupus nephritis.
  • Ocular formulation of voclosporin, aimed at treating dry eye syndrome.
  • Research programs focusing on the applications of voclosporin in other autoimmune diseases.
  • Partnerships for the commercialization and distribution of Lupkynis outside of the United States.
  • Patient support and assistance programs designed to improve access to treatments for lupus nephritis.

Aurinia Pharmaceuticals executive team

  • Mr. Peter S. Greenleaf M.B.A.President, CEO & Director
  • Mr. Joseph M. Miller CPAChief Financial Officer
  • Mr. Matthew Maxwell Donley M.B.A.Chief Operations Officer
  • Mr. Stephen P. RobertsonExecutive VP, General Counsel, Corporate Secretary & Chief Compliance Officer
  • Dr. Gregory F. Keenan M.D.Chief Medical Officer
  • Ms. Andrea Levin ChristopherExecutive Director of Corporate Communications & Investor Relations
  • Dr. Premchandran Ramiya Ph.D.Senior Vice President of Manufacturing & Supply Chain

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.